Matches in Nanopublications for { ?s ?p ?o <http://bio2rdf.org/drugbank_resource:DB00502_DB00656_nanopub.RAOcOvQ9T0hyqDLKPseRN04D6ZtTfow52f2qT23dDdhLE#assertion>. }
Showing items 1 to 6 of
6
with 100 items per page.
- drugbank_resource:DB00502_DB00656 type drugbank_vocabulary:Drug-Drug-Interaction assertion.
- drugbank_resource:DB00502_DB00656 label "DDI between Haloperidol and Trazodone - The CYP3A4 inhibitor, Haloperidol, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. The CYP2D6 inhibitor, Trazodone, may increase the efficacy of Haloperidol by decreasing Haloperidol metabolism and clearance. Monitor for changes in Trazodone and Haloperidol efficacy/toxicity if either agent is initiated, discontinued or dose changed. [drugbank_resource:DB00502_DB00656]" assertion.
- drugbank_resource:DB00502_DB00656 identifier "drugbank_resource:DB00502_DB00656" assertion.
- drugbank_resource:DB00502_DB00656 title "DDI between Haloperidol and Trazodone - The CYP3A4 inhibitor, Haloperidol, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. The CYP2D6 inhibitor, Trazodone, may increase the efficacy of Haloperidol by decreasing Haloperidol metabolism and clearance. Monitor for changes in Trazodone and Haloperidol efficacy/toxicity if either agent is initiated, discontinued or dose changed." assertion.
- drugbank:DB00502 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB00502_DB00656 assertion.
- drugbank:DB00656 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB00502_DB00656 assertion.